Open-capsule budesonide for the treatment of immune-related enteritis from checkpoint inhibitors
Background Limited data exist for management strategies targeting immunotherapy-related enteritis (irEnteritis). Systemic corticosteroids are commonly used but often are limited by adverse events. Enteric corticosteroids such as budesonide offer an attractive alternative; however, the ileocolonic re...
Saved in:
| Main Authors: | Amitabh Srivastava, Michael Postow, David Faleck, Patrick Tiongco Magahis, Tara Corso, Pamela Livingstone, Erika Tom |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-07-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/12/7/e009051.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Exploring the molecular mechanism of budesonide enteric capsules in the treatment of IgA nephropathy based on bioinformatics
by: Mengshu Lin, et al.
Published: (2025-08-01) -
WCN25-3679 Open label, single arm, multicenter, prospective study on oral enteric coated budesonide therapy for primary IgA nephropathy
by: SANSHRITI CHAUHAN, et al.
Published: (2025-02-01) -
Comparison of Budesonide Turbuhaler with Budesonide Aqua in the Treatment of Seasonal Allergic Rhinitis
by: William H Yang, et al.
Published: (1998-01-01) -
Enteritis of the ileal conduit as an adverse event related to immune checkpoint inhibitor use
by: Ko Kobayashi, et al.
Published: (2025-01-01) -
Budesonide for the Treatment of Inflammatory Bowel Disease
by: Gordon R Greenberg
Published: (1994-01-01)